---
title: Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention
nct_id: NCT04450888
overall_status: COMPLETED
phase: NA
sponsor: West China Hospital
study_type: INTERVENTIONAL
primary_condition: Cardiovascular Disease
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04450888.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04450888"
ct_last_update_post_date: 2022-03-10
last_seen_at: "2026-05-12T06:15:08.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention

**Official Title:** Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention(EMT-OCSP): a Pragmatic,Multi-centre, Observer-blinded,12-month Randomised Controlled Study

**NCT ID:** [NCT04450888](https://clinicaltrials.gov/study/NCT04450888)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 13114
- **Lead Sponsor:** West China Hospital
- **Collaborators:** Centers for Disease Control and Prevention, China, Beijing Tiantan Hospital, First Affiliated Hospital of Chongqing Medical University, China Stroke Databank Center
- **Conditions:** Cardiovascular Disease, Stroke, Primary Prevention
- **Start Date:** 2020-07-01
- **Completion Date:** 2022-01-22
- **CT.gov Last Update:** 2022-03-10

## Brief Summary

Effects of Message framing and Time discounting on heath communication for Optimum Cardiovascular disease and Stroke Prevention（EMT-OCSP）is a pragmatic, 2 × 2 factorial, randomized, controlled, observer blinded, multicenter trial with four parallel groups. It aims to determine if risk and intervention communication strategy（gain-framed versus loss-frame, long-term context versus short-term context and the potential interaction）have different effect on optimizing adherence to clinical preventive management （in the endpoint of CVD risk reduction）for subjects with at least one moldable risk factor for CVD.

## Detailed Description

Scientific title Effects of Message framing and Time discounting on health communication for Optimum Cardiovascular disease and Stroke Prevention(EMT-OCSP): a pragmatic randomised controlled study

Principal Investigator Li He

Study period 2020-07-01-2022-01-21

Hypotheses and aims When communicating cardiovascular disease（CVD）risk to individuals, different presentation of information carries its own connotations and biases. The one or the other pattern of the presentation may affect individuals' decision making.This study aims to determine if risk and intervention communication strategy（gain-framed versus loss-frame, long-term context versus short-term context and the potential interaction）have different effect on optimizing adherence to clinical preventive management （in the endpoint of CVD risk reduction）for subjects with at least one moldable risk factor for CVD. We aim to provide evidence for practitioners regarding messaging strategies that improve communication effectiveness and further reduce the risk of CVD events in the population, as well as to develop more effective communication strategies for groups of people with different characteristics to maximise patient adherence to lifestyle modifications and medical treatment.

Primary outcome Ten-year CVD risk, lifetime CVD risk and CVD-free life expectancy after 1 year according to the LIFE-CVD model.

Secondary outcomes CVD risk factors \[blood pressure(BP) and serum cholesterol, low-density lipoprotein (LDL), non-high-density lipoprotein (HDL), triglycerides and fasting glucose levels\],lifestyle factors (physical activity, tobacco use, alcohol use and eating habits), pharmacological treatments for hypertension, dyslipidaemia and diabetes, and anti-thrombotic drug prescriptions after 1 year.

Study design The EMT-OCSP trial is designed as a pragmatic, 2 × 2 factorial, randomized, controlled, observer blinded, multicenter trial with four parallel groups. Randomization will be performed as block randomization with a 1:1:1:1 allocation.

Study population and sample size Subjects with at least one moldable risk factor for CVD. The sample size calculations revealed that the enrolment of 15,000 participants would be sufficient, allowing for a 20% drop-out rate.

Follow-up period One year

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* aged 45-80 years,
* personally own and use a smartphone (Apple or Android platform) with Internet access,
* and have at least one of the following CVD risk factors: history of CVD at age \< 60 years in a first-degree relative, smoking, diabetes, hypertension, and low-density lipoprotein (LDL)cholesterol ≥ 4.5 mmol/L.

Exclusion Criteria:

* participants with histories of CVD, heart failure, or chronic kidney disease (estimated glomerular filtration rate \< 30 mL/min/1.73m2);
* those with terminal malignancy at baseline;
* those with severe psychological or mental disorders
* violation of the study protocol and participation in another clinical study during follow-up
```

## Arms

- **Model A** (OTHER) — Total cardiovascular disease (CVD)-free life expectancy gain in one's remaining life.
- **Model B** (OTHER) — Average CVD-free life expectancy gain per year.
- **Model C** (OTHER) — Total CVD-free life expectancy loss that can be reclaimed in one's remaining life.
- **Model D** (OTHER) — Average CVD-free life expectancy loss that can be reclaimed per year.

## Interventions

- **The strategic use of messages in risk communication** (OTHER) — The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.

## Primary Outcomes

- **10-year CVD risk** _(time frame: At the 1-year follow-up)_
- **Lifetime CVD risk** _(time frame: At the 1-year follow-up)_
- **CVD-free life expectancy** _(time frame: At the 1-year follow-up)_

## Secondary Outcomes

- **Changes in systolic and diastolic blood pressure** _(time frame: At the 1-year follow-up)_
- **Changes in serum cholesterol level** _(time frame: At the 1-year follow-up)_
- **Changes in serum LDL level** _(time frame: At the 1-year follow-up)_
- **Changes in serum non-HDL level** _(time frame: At the 1-year follow-up)_
- **Changes in serum triglycerides level** _(time frame: At the 1-year follow-up)_
- **Changes in fasting glucose level** _(time frame: At the 1-year follow-up)_
- **Changes in physical activity (International Physical Activity Questionnaire or International Physical Activity Questionnaire Short Version Modified for Elderly)** _(time frame: At the 1-year follow-up)_
- **Changes in tobacco use** _(time frame: At the 1-year follow-up)_
- **Changes in alcohol use (AUDIT questionnaire)** _(time frame: At the 1-year follow-up)_
- **Changes in dietary habits (food frequency questionnaire)** _(time frame: At the 1-year follow-up)_
- **Changes adherence to pharmacological treatments for hypertension (proportion of persistent medication user）** _(time frame: At the 1-year follow-up)_
- **Changes adherence to pharmacological treatments for dyslipidaemia (proportion of persistent medication user）** _(time frame: At the 1-year follow-up)_
- **Changes adherence to pharmacological treatments for diabetes (proportion of persistent medication user）** _(time frame: At the 1-year follow-up)_
- **Changes adherence to anti-thrombotic therapy (proportion of persistent medication user）** _(time frame: At the 1-year follow-up)_

## Locations (1)

- Health center of Sipo town, Yibin, Sichuan, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.health center of sipo town|yibin|sichuan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04450888.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04450888*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*